SEARCH

SEARCH BY CITATION

References

  • 1
    Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 2007; 84: 197215
  • 2
    Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011; 81: 12711278
  • 3
    Arcangeli S, Strigari L, Gomellini S et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84: 11721178
  • 4
    Zelefsky MJ, Kollmeier M, Cox B et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84: 125129
  • 5
    Bauman G, Rumble RB, Chen J, Loblaw A, Warde P, Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll Radiol) 2012; 24: 461473
  • 6
    Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (‘trifecta’). Urology 2005; 66 (Suppl.): 8394
  • 7
    Ficarra V, Sooriakumaran P, Novara G et al. Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification. Eur Urol 2012; 61: 541548
  • 8
    Pollack A, Hanlon AL, Horwitz EM et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006; 64: 518526
  • 9
    Jereczek-Fossa BA, Zerini D, Fodor C et al. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation. Urol Oncol 2011; 29: 523532
  • 10
    Jereczek-Fossa BA, Santoro L, Zerini D et al. Image-guided hypofractionated radiotherapy and quality of life in localized prostate cancer: prospective longitudinal study on 337 patients. J Urol 2013; 189: 20992103
  • 11
    Chavaudra J, Bridier A. Definition of volumes in external radiotherapy: ICRU reports 50 and 62. Cancer Radiother 2001; 5: 472478
  • 12
    Roach M 3rd, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J RadiatOncol Biol Phys 2006; 65: 965974
  • 13
    National Comprehensive Cancer Network. Prostate cancer. National Comprehensive Cancer network Clinical Practice Guidelines in Oncology. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed April 2013
  • 14
    van Tol-Geerdink JJ, Leer JW, van Lin EN et al. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being. Int J Radiat Oncol Biol Phys 2008; 70: 442448
  • 15
    Patel VR, Coelho RF, Chauhan S et al. Continence, potency and oncological outcomes after robotic-assisted radical prostatectomy: early trifecta results of a high-volume surgeon. BJU Int 2010; 106: 696702
  • 16
    Jereczek-Fossa BA, Badzio A, Jassem J. Time without symptoms and toxicity (TWIST) analysis in postoperative irradiation for endometrial cancer. Radiother Oncol 2004; 72: 175181
  • 17
    National Institute for Health Research. The ProtecT trial – Evaluating the effectiveness of treatment for clinically localised prostate cancer. Available at: http://www.hta.ac.uk/1230. Accessed April 2013